Assay of OAZ1 mRNA levels in chronic myeloid leukemia combined with application of leukemia PCR array identified relevant gene changes affected by antizyme

Acta Haematologica

Volumn 131, Issue 3, 2014, Pages 141-147

  Wu, Bingping ^b   Wang, Xing ^a   Ma, Wenli ^b   Zheng, Wenling ^b   Jiang, Li ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Chronic myeloid leukemia; Human leukemia PCR array; Ornithine decarboxylase antizyme

Indexed keywords

ANTIZYME; CDH13 PROTEIN; DAPK1 PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IKZF3 PROTEIN; OAZ1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ARACHIDONATE 5 LIPOXYGENASE; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; BRAIN AND ACUTE LEUKEMIA CYTOPLASMIC PROTEIN; CADHERIN; CADHERIN 13 H CADHERIN; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 3; CONNECTIVE TISSUE GROWTH FACTOR; DEATH ASSOCIATED PROTEIN KINASE; DEATH ASSOCIATED PROTEIN KINASE 1; EARLY GROWTH RESPONSE 3; HEMATOPOIETIC CELL KINASE; IKAROS FAMILY ZINC FINGER 3; INTERLEUKIN 1 RECEPTOR TYPE I; JUN B PROTO ONCOGENE; MESSENGER RNA; NUCLEAR RECEPTOR NR4A3; ORNITHINE DECARBOXYLASE ANTIZYME 1; PROTEIN; SMOOTHENED FRIZZLED FAMILY RECEPTOR; T CELL LEUKEMIA HOMEOBOX 1; T CELL LEUKEMIA HOMEOBOX 3; TRANSCRIPTION FACTOR RUNX1; ZINC FINGER PROTEIN;

APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULTRAVIOLET SPECTROPHOTOMETRY; UPREGULATION; WESTERN BLOTTING; CANCER CLASSIFICATION; DISEASE COURSE; GENE IDENTIFICATION; IN VITRO STUDY; K562 CELL LINE; LEUKEMIA POLYMERASE CHAIN REACTION ARRAY; PATHOGENESIS; TREATMENT RESPONSE;

APOPTOSIS; CASE-CONTROL STUDIES; CHEMOKINE CXCL10; DOWN-REGULATION; ERYTHROPOIESIS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84886740919     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000353406     Document Type: Article

References (19)

1. Liu YC, Hsu DH, Huang CL: Determinants of the differential antizyme-binding affinity of ornithine decarboxylase. PLoS One 2011; 6:e26835.
2. Schipper RG, Cuijpers VM, De Groot LH: Intracellular localization of ornithine decarboxylase and its regulatory protein, antizyme-1. J Histochem Cytochem 2004: 52: 1259-1266.
3. Lin Y, Martin J, Gruendler C: A novel link between the proteasome pathway and the signal transduction pathway of the bone morphogenetic proteins (BMPs). BMC Cell Biol 2002; 3: 15.
4. Newman RM, Mobascher A, Mangold U: Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem 2004; 279: 41504-41511.
5. Matsufuji S, Matsufuji T, Miyazaki Y: Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 1995; 80: 51-60.
6. Kurian L, Palanimurugan R, Godderz D: Polyamine sensing by nascent ornithine decarboxylase antizyme stimulates decoding of its mRNA. Nature 2011; 477: 490-494.
7. Rato C, Amirova SR, Bates DG: Translational recoding as a feedback controller: systems approaches reveal polyamine-specific effects on the antizyme ribosomal frameshift. Nucleic Acids Res 2011; 39: 4587-4597.
8. Liu GY, Liao YF, Hsu PC: Antizyme, a natural ornithine decarboxylase inhibitor, induces apoptosis of haematopoietic cells through mitochondrial membrane depolarization and caspases' cascade. Apoptosis 2006; 11: 1773-1788.
9. Jabbour E, Saglio G, Radich J: Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk 2012; 12: 223-229.
10. Naud JS, Ghani K, de Campos-Lima PO: Nilotinib and imatinib inhibit cytarabine cellular uptake: implications for combination therapy. Leuk Res 2012; 36: 1311-1314.
11. Agostinelli E, Marques MP, Calheiros R: Polyamines: fundamental characters in chemistry and biology. Amino Acids 2010; 38: 393-403.
12. Olsen RR, Zetter BR: Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer. Mol Cancer Res 2011; 9: 1285-1293.
13. Meulmeester E, Ten Dijke P: The dynamic roles of TGF-beta in cancer. J Pathol 2011; 223: 205-218.
14. Su E, Han X, Jiang G: The transforming growth factor beta 1/SMAD signaling pathway involved in human chronic myeloid leukemia. Tumori 2010; 96: 659-666.
15. Howard OM, Ben-Baruch A, Oppenheim JJ: Chemokines: progress toward identifying molecular targets for therapeutic agents. Trends Biotechnol 1996; 14: 46-51.
16. Liu M, Guo S, Stiles JK: The emerging role of CXCL10 in cancer (Review). Oncol Lett 2011; 2: 583-589.
17. McClatchie G: An epidemiological database system. Int J Biomed Comput 1978; 9: 11-24.
18. Tsuji T, Usui S, Aida T: Induction of epithelial differentiation and DNA demethylation in hamster malignant oral keratinocyte by ornithine decarboxylase antizyme. Oncogene 2001; 20: 24-33.
19. Yamamoto D, Shima K, Matsuo K: Ornithine decarboxylase antizyme induces hypomethylation of genome DNA and histone H3 lysine 9 dimethylation (H3K9me2) in human oral cancer cell line. PLoS One 2010; 5:e12554.